Press Release: Omeros : Omeros Corporation Provides Update of Ongoing Zaltenibart Phase 3 PNH Clinical Trial Program
Omeros Corporation (Nasdaq: OMER) today reported that clinical trial site activation for enrollment is underway for the company's Phase 3 program evaluating
Read full article »
Omeros is a Wasington-based biopharmaceutical company that researches and develops small-molecule and protein therapeutics for the treatment of inflammation and CNS disorders.
Read more